Cargando…

Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich’s Ataxia

The thioredoxin family consists of a small group of redox proteins present in all organisms and composed of thioredoxins (TRXs), glutaredoxins (GLRXs) and peroxiredoxins (PRDXs) which are found in the extracellular fluid, the cytoplasm, the mitochondria and in the nucleus with functions that include...

Descripción completa

Detalles Bibliográficos
Autores principales: Seco-Cervera, Marta, González-Cabo, Pilar, Pallardó, Federico V., Romá-Mateo, Carlos, García-Giménez, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763308/
https://www.ncbi.nlm.nih.gov/pubmed/33321938
http://dx.doi.org/10.3390/antiox9121257
_version_ 1783627987716931584
author Seco-Cervera, Marta
González-Cabo, Pilar
Pallardó, Federico V.
Romá-Mateo, Carlos
García-Giménez, José Luis
author_facet Seco-Cervera, Marta
González-Cabo, Pilar
Pallardó, Federico V.
Romá-Mateo, Carlos
García-Giménez, José Luis
author_sort Seco-Cervera, Marta
collection PubMed
description The thioredoxin family consists of a small group of redox proteins present in all organisms and composed of thioredoxins (TRXs), glutaredoxins (GLRXs) and peroxiredoxins (PRDXs) which are found in the extracellular fluid, the cytoplasm, the mitochondria and in the nucleus with functions that include antioxidation, signaling and transcriptional control, among others. The importance of thioredoxin family proteins in neurodegenerative diseases is gaining relevance because some of these proteins have demonstrated an important role in the central nervous system by mediating neuroprotection against oxidative stress, contributing to mitochondrial function and regulating gene expression. Specifically, in the context of Friedreich’s ataxia (FRDA), thioredoxin family proteins may have a special role in the regulation of Nrf2 expression and function, in Fe-S cluster metabolism, controlling the expression of genes located at the iron-response element (IRE) and probably regulating ferroptosis. Therefore, comprehension of the mechanisms that closely link thioredoxin family proteins with cellular processes affected in FRDA will serve as a cornerstone to design improved therapeutic strategies.
format Online
Article
Text
id pubmed-7763308
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77633082020-12-27 Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich’s Ataxia Seco-Cervera, Marta González-Cabo, Pilar Pallardó, Federico V. Romá-Mateo, Carlos García-Giménez, José Luis Antioxidants (Basel) Review The thioredoxin family consists of a small group of redox proteins present in all organisms and composed of thioredoxins (TRXs), glutaredoxins (GLRXs) and peroxiredoxins (PRDXs) which are found in the extracellular fluid, the cytoplasm, the mitochondria and in the nucleus with functions that include antioxidation, signaling and transcriptional control, among others. The importance of thioredoxin family proteins in neurodegenerative diseases is gaining relevance because some of these proteins have demonstrated an important role in the central nervous system by mediating neuroprotection against oxidative stress, contributing to mitochondrial function and regulating gene expression. Specifically, in the context of Friedreich’s ataxia (FRDA), thioredoxin family proteins may have a special role in the regulation of Nrf2 expression and function, in Fe-S cluster metabolism, controlling the expression of genes located at the iron-response element (IRE) and probably regulating ferroptosis. Therefore, comprehension of the mechanisms that closely link thioredoxin family proteins with cellular processes affected in FRDA will serve as a cornerstone to design improved therapeutic strategies. MDPI 2020-12-10 /pmc/articles/PMC7763308/ /pubmed/33321938 http://dx.doi.org/10.3390/antiox9121257 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Seco-Cervera, Marta
González-Cabo, Pilar
Pallardó, Federico V.
Romá-Mateo, Carlos
García-Giménez, José Luis
Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich’s Ataxia
title Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich’s Ataxia
title_full Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich’s Ataxia
title_fullStr Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich’s Ataxia
title_full_unstemmed Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich’s Ataxia
title_short Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich’s Ataxia
title_sort thioredoxin and glutaredoxin systems as potential targets for the development of new treatments in friedreich’s ataxia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763308/
https://www.ncbi.nlm.nih.gov/pubmed/33321938
http://dx.doi.org/10.3390/antiox9121257
work_keys_str_mv AT secocerveramarta thioredoxinandglutaredoxinsystemsaspotentialtargetsforthedevelopmentofnewtreatmentsinfriedreichsataxia
AT gonzalezcabopilar thioredoxinandglutaredoxinsystemsaspotentialtargetsforthedevelopmentofnewtreatmentsinfriedreichsataxia
AT pallardofedericov thioredoxinandglutaredoxinsystemsaspotentialtargetsforthedevelopmentofnewtreatmentsinfriedreichsataxia
AT romamateocarlos thioredoxinandglutaredoxinsystemsaspotentialtargetsforthedevelopmentofnewtreatmentsinfriedreichsataxia
AT garciagimenezjoseluis thioredoxinandglutaredoxinsystemsaspotentialtargetsforthedevelopmentofnewtreatmentsinfriedreichsataxia